OBJECTIVE: Minimally invasive repair of mitral valve prolapse (MVP) causing severe mitral regurgitation (MR) should reduce MR and have chronic durability. Our ex vivo, acute in vivo, and chronic in vivo studies suggest that direct application of radiofrequency ablation (RFA) to mitral leaflets and chordae can effect these repair goals to decrease MR. METHODS: A total of seven canines were studied to assess the effects of RFA on mitral valve structure and function. RFA was applied ex vivo (n = 1), acutely in vivo using a right lateral thoracotomy and cardiopulmonary bypass (n = 3), and chronically in vivo using percutaneous access to the heart (n = 3). RFA was applied to the mitral valve and its associated chordae. Mitral valve structure and function (in vivo preparations) were then assessed. RESULTS: Ex vivo application of RFA resulted in qualitative reduction in mitral leaflet surface area and chordal length. Acute in vivo application of RFA to canines found to have MVP causing severe MR demonstrated a 43.7-60.7% statistically significant (P = 0.039) reduction in postablation MR. Chronic, in vivo, percutaneous application of RFA was found to be feasible and the engendered alterations durable. CONCLUSION: These data suggest that myxomatous mitral valve repair using radiofrequency energy delivered via catheter is feasible.
OBJECTIVE: Minimally invasive repair of mitral valve prolapse (MVP) causing severe mitral regurgitation (MR) should reduce MR and have chronic durability. Our ex vivo, acute in vivo, and chronic in vivo studies suggest that direct application of radiofrequency ablation (RFA) to mitral leaflets and chordae can effect these repair goals to decrease MR. METHODS: A total of seven canines were studied to assess the effects of RFA on mitral valve structure and function. RFA was applied ex vivo (n = 1), acutely in vivo using a right lateral thoracotomy and cardiopulmonary bypass (n = 3), and chronically in vivo using percutaneous access to the heart (n = 3). RFA was applied to the mitral valve and its associated chordae. Mitral valve structure and function (in vivo preparations) were then assessed. RESULTS: Ex vivo application of RFA resulted in qualitative reduction in mitral leaflet surface area and chordal length. Acute in vivo application of RFA to canines found to have MVP causing severe MR demonstrated a 43.7-60.7% statistically significant (P = 0.039) reduction in postablation MR. Chronic, in vivo, percutaneous application of RFA was found to be feasible and the engendered alterations durable. CONCLUSION: These data suggest that myxomatous mitral valve repair using radiofrequency energy delivered via catheter is feasible.
Authors: Aubrey C Galloway; Eugene A Grossi; Costas S Bizekis; Greg Ribakove; Patricia Ursomanno; Julie Delianides; F Gregory Baumann; Frank C Spencer; Stephen B Colvin Journal: Ann Surg Date: 2002-09 Impact factor: 12.969
Authors: Octavio A Victal; John R Teerlink; Efrain Gaxiola; Arthur W Wallace; Sergio Najar; David H Camacho; Augustin Gutierrez; Gabriel Herrera; Gustavo Zuniga; Fausto Mercado-Rios; Mark B Ratcliffe Journal: Circulation Date: 2002-03-19 Impact factor: 29.690
Authors: R B Devereux; E C Jones; M J Roman; B V Howard; R R Fabsitz; J E Liu; V Palmieri; T K Welty; E T Lee Journal: Am J Med Date: 2001-12-15 Impact factor: 4.965
Authors: Lisa A Freed; Emelia J Benjamin; Daniel Levy; Martin G Larson; Jane C Evans; Deborah L Fuller; Birgitta Lehman; Robert A Levine Journal: J Am Coll Cardiol Date: 2002-10-02 Impact factor: 24.094
Authors: Steven M Boronyak; Joseph L Fredi; Michael N Young; Douglas M Dumont; Phillip E Williams; Brett C Byram; W David Merryman Journal: Ann Biomed Eng Date: 2015-10-27 Impact factor: 3.934